Meeting
2017 Genitourinary Cancers Symposium
Management of high-risk prostate cancer with 5-treatment stereotactic body radiotherapy: Long-term results.
Authors
Josephine Kang
Weill Cornell Medical College, New York, NY
Josephine Kang , Alan J. Katz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 94)
DOI
10.1200/JCO.2017.35.6_suppl.94
Abstract #
94
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.
First Author: Luca Faustino Valle
Poster
2019 Genitourinary Cancers Symposium
Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy.
First Author: Naomi Y Jiang
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz
Poster
2020 Genitourinary Cancers Symposium
Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes.
First Author: Andrew Loblaw